Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

1. Age ≥18 years of age at the time of signing the informed consent.

2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).

1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation

2. Self-reported body weight change of 5% or more within 3 months of screening

3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (excluding liposuction or abdominoplasty if performed >1 year prior to screening)

4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)

5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy

6. Treatment with glucose-lowering agent(s) within 90 days before screening

7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

8. History of acute or chronic pancreatitis